Table 5.

Changes in inflammatory biomarkers after 1 year, associated with tertiles of changes in total polyphenol excreted, T2 (–14.04 to 31.56) and T3 (>31.57) compared with T1 (<–14.03)

	Model	B	P	95% CI
VCAM‐1, ng ml –1	Model 1
	T2 vs. T1	–7.18	0.066	–14.84 to 0.48
	T3 vs. T1	–9.64	0.016	–17.46 to –1.82
	Model 2
	T2 vs. T1	–8.45	0.045	–16.73 to –0.18
	T3 vs. T1	–9.47	0.019	–17.38 to –1.56
ICAM‐1, ng ml –1	Model 1
	T2 vs. T1	–10.91	0.009	–19.10 to –2.72
	T3 vs. T1	–11.78	0.006	–20.20 to –3.36
	Model 2
	T2 vs. T1	–10.18	0.034	–19.60 to –0.77
	T3 vs. T1	–14.71	0.002	–23.88 to –5.53
IL‐6, pg ml –1	Model 1
	T2 vs. T1	–0.95	0.009	–1.67 to –0.24
	T3 vs. T1	–1.23	0.001	–1.96 to –0.51
	Model 2
	T2 vs. T1	–0.99	0.019	–2.03 to –0.40
	T3 vs. T1	–1.21	0.004	–1.85 to –0.21
TNF‐α, pg ml –1	Model 1
	T2 vs. T1	–4.46	0.003	–7.39 to –1.53
	T3 vs. T1	–5.93	<0.001	–8.92 to –2.94
	Model 2
	T2 vs. T1	–5.88	<0.001	–9.17 to –2.58
	T3 vs. T1	–7.05	<0.001	–10.35 to –3.75
MCP‐1, pg ml –1	Model 1
	T2 vs. T1	–3.32	0.009	–4.20 to 0.75
	T3 vs. T1	–2.98	0.021	–3.84 to 1.20
	Model 2
	T2 vs. T1	–3.55	0.012	–4.68 to 0.82
	T3 vs. T1	–3.36	0.017	–4.55 to 0.92

B, nonstandardized coefficient; CI, confidence interval; Model 1, unadjusted; Model 2: adjusted by baseline inflammatory biomarkers, intervention group, gender, age, body mass index, smoking status, physical activity, medication use (antihypertensive agents, statins or other hypolipidaemic drugs, insulin, oral hypoglycaemic drugs, and aspirin or other antiplatelet drugs) supplements taken in the previous month, and sodium, potassium, total energy, monounsaturated fatty acid, polyunsaturated fatty acid and saturated fatty acid intake; P, two‐sided test of significance.